TransCode adjourns annual meeting to July 20 pending Nasdaq approval of stock conversion

Transcode Therapeutics, Inc.

Annual meeting adjourned from July 2 to July 20, 2026, at 9:30 a.m. ET.
All proposals have received necessary stockholder support, but Nasdaq has not yet approved initial listing application for conversion of Series A and B preferred stock to common.
Company believes it meets Nasdaq Capital Market initial listing criteria, but no assurance of outcome or timing.
Record date remains May 28, 2026; stockholders who haven't voted can vote via proxy or at reconvened meeting.
No changes to proposals; company continues soliciting votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.